4dmedical Ltd. · ASX:4DX
4dmedical — Investor Presentation (August 2020)
37 slides from 4dmedical's investor presentation, Aug 10, 2020
Slide 1: Investor Presentation August 2020
For personal use only Investor Presentation August 2020 ASX: 4DX 4DMedical Limited | ABN 31 161 684 831
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by 4Dx Limited (ACN 161 684 831) (Company or 4DMedical). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate For personal use only (Group) a
Slide 3: Introduction to 4DMedical
Introduction to 4DMedical For personal use only • Founded in 2012, 4DMedical Limited is a Melbourne-based software technology company focused on creating a step change in the capacity of physicians to diagnose and manage patients with diseases of the lung • The respiratory diagnostic sector represen
Slide 4: Respiratory Diagnostics Market Overview
For personal use only Respiratory Diagnostics Market Overview
Slide 5: Global Lung Diagnostic Market Opportunity
Respiratory Diagnostics Market Overview Global Lung Diagnostic Market Opportunity For personal use only 4DMedical’s core initial focus is rapid penetration of the US market. Given the large market size, even low market penetration could see substantial revenue generation with high gross margin. (Tho
Slide 6: Existing Lung Diagnostics are Failing Us
Respiratory Diagnostics Market Overview Existing Lung Diagnostics are Failing Us For personal use only Over the last 200 years, advances in medical diagnostic technology have delivered dramatic benefits for mankind whilst advancements in lung diagnostics have stagnated. The current gold standard mod
Slide 7: Pulmonary Function Test and X-ray Technology
Respiratory Diagnostics Market Overview Pulmonary Function Test X-ray Technology For personal use only Accurate, but insensitive Inexpensive, but tells us very little Overview First invented in 1846,the Overview advancement of the Invented in 1895, the X-ray is spirometer facilitated the widely used
Slide 8: CT Technology and Nuclear Medicine
Respiratory Diagnostics Market Overview CT Technology Nuclear Medicine For personal use only Sensitive, but expensive and Capability to measure ventilation high radiation dose and perfusion, but significant limitations Overview Invented in 1971, computed Overview tomography (CT) technology is Invent
Slide 9: Introduction to XV Technology
For personal use only Introduction to
Slide 10: XV Technology Overview
Introduction to XV Technology XV Technology Overview For personal use only • XV Technology allows physicians to understand regional air flow within the lung, and to identify respiratory deficiencies earlier and with greater sensitivity, creating a step change in the capacity of physicians to diagnos
Slide 11: XV Technology Demonstration
Introduction to XV Technology XV Technology Demonstration For personal use only Healthy Lung Diseased Lung Subtle defect Uniform ventilation Compensation Defect Pg 11 | Investor presentation
Slide 12: Advantages of existing modalities, in a single platform
Introduction to XV Technology Advantages of existing modalities, in a single platform For personal use only Functional insight Comparable High-detail of spirometry radiation dose resolution at a regional level to X-ray of a CT scan Faster, more efficient testing Competitive pricing Improved clinical
Slide 13: Testimonials
Introduction to XV Technology Testimonials For personal use only "4DMedical lung imaging technology provides a rare and exciting opportunity to improve lung health outcomes for patients globally" Professor Greg Snell Head of Lung Transplant Service, Alfred Hospital “There is a global need for a high
Slide 14: Company Overview
For personal use only Company Overview
Slide 15: 4DMedical origins & history
Company Overview 4DMedical origins & history For personal use only A fifteen year journey from conception to commercialisation First commercial agreement to collaborate with major US hospital signed with Cedars Sinari 510(k) FDA submission made First major order received for a preclinical scanner Im
Slide 16: SaaS Business Model Designed For Rapid Uptake
Company Overview SaaS Business Model Designed For Rapid Uptake For personal use only Our business model is designed for rapid penetration of the lung diagnostics market, with no upfront costs borne by hospitals for installation and a ‘pay as you go model’ which avoids the capital budgets of the hosp
Slide 17: 4DMedical Cloud Based Workflow
Company Overview 4DMedical Cloud Based Workflow For personal use only • 4DMedical imaging protocol is agnostic to hospital X-ray hardware • X-ray equipment transmits image to PACS (Picture Archive and Communication System) as per industry standard • Fully automated workflow from PACS to PACS via 3rd
Slide 18: XV Platform Product Pipeline
Company Overview XV Platform Product Pipeline For personal use only The XV Technology platform provides for the rapid deployment of product for various indications. XV Ventilation Analysis (XV) – FDA Clearance obtained • The XV Ventilation Analysis provides physicians a patient’s regional measuremen
Slide 19: Significant Barriers to Entry
Company Overview Significant Barriers to Entry For personal use only First mover advantage, comprehensive patent protection and strong product pipeline provide significant barriers to entry for 4DMedical’s target market using XV technology First mover advantage Clinical Validation • First mover adva
Slide 20: Board and Management Team
For personal use only Board and Management Team
Slide 21: Board and Management: Board of Directors and Advisory Board
Board and Management 4DMedical Board of Directors Advisory Board For personal use only DR. SAM HUPERT Advisory Board Member Co-founder and Chief Executive Officer of Pro Medicus Ltd (PME.ASX) which develops and BRUCE RATHIE ANDREAS FOURAS, PhD LIL BIANCHI DR. ROBERT A. FIGLIN, MD markets health imag
Slide 22: 4DMedical Executive Team
Board and Management 4DMedical Executive Team For personal use only ANDREAS FOURAS, PhD HEATH LEE PAUL COOKE R. AIDAN JAMISON, PhD Managing Director & CEO Executive Director & CFO Senior Vice President, Senior Vice President, Engineering Award-winning aerospace engineer and Qualified Chartered Accou
Slide 23: Capital Structure
Corporate Capital Structure Major Shareholders For personal use only Ticker 4DX Andreas Fouras 24.49% Share Price at IPO $0.73 Top 20 shareholders 54.75% Shares on Issue (m) 264.76 Options on Issue (m) 20.67 Senior Management Team Market Capitalisation at IPO $193m Andreas Fouras Managing Director &
Slide 24: Commercialisation Strategy
For personal use only Commercialisation Strategy
Slide 25: Compelling Value Proposition For USA Healthcare System
Commercialisation Strategy Compelling Value Proposition For USA Healthcare System For personal use only Improved Patient Experience Improved Patient Outcomes • Non-invasive and fast imaging protocol - • Technology has FDA Clearance for all lung with simple to understand report outputs conditions to
Slide 26: US Lung Diagnostic Market Opportunity
Commercialisation Strategy ✓ 73 million respiratory diagnostic tests undertaken each US Lung Diagnostic year in the US For personal use only Market Opportunity ✓ 6,176 hospitals, each with an average of ~150 hospital beds • 4DMedical’s initial core focus is the rapid penetration of the US market. ✓
Slide 27: USA Commercialisation Strategy
Commercialisation Strategy USA Commercialisation Strategy For personal use only Stage 1 Stage 2 Stage 3 Stage 4 Clinical Trials at Pilot Solution and National Accelerate Flagship US sites Launch 1st Product Expansion Adoption • Already installed and • Pre-launch pilot • Expand sales team to • Obtain
Slide 28: US Clinical Trial Partners
Commercialisation Strategy US Clinical Trial Partners For personal use only • 4DMedical has existing partnerships with some of the largest and most prestigious hospitals in the US • Existing eight clinical trial partners represent approximately 1% of US hospitals beds, and 1% of the US market revenu
Slide 29: Future Growth Avenues
For personal use only Future Growth Avenues
Slide 30: Increased Functionality, Indications and Regions
Future Growth Avenues Increased Functionality, Indications and Regions For personal use only Increased functionality of existing XV (ventilation) product Expansion of global presence • Ability to provide additional functionality to the existing XV • SaaS business model allows for global scale up thr
Slide 31: COVID-19 – A Fundamental Tailwind
Future Growth Avenues COVID -19 – A Fundamental Tailwind For personal use only • The COVID-19 pandemic has created a significant increase in demand for global demand for lung health technology • In particular, the US has been one of the hardest-hit countries in terms of confirmed cases (~26% of the
Slide 32: Future Catalysts & Milestones
Future Growth Avenues Future Catalysts & Milestones For personal use only Beta site (soft product launch) Commence TGA & CE Mark Ongoing sale of XV, CFPA & to de-risk market entry process for XV Ventilation VQ products in the US product XV Ventilation product Launch of XV Ventilation product Appoint
Slide 33: Investment Summary
Investment Summary For personal use only 1• Clinically validated, FDA Clearance technology offering superior outcomes at lower costs compared with incumbent technologies 2• Significant global market with attractive growth drivers in core geographic regions 3• Capital light sales model underpinned by
Slide 34: Appendix
For personal use only Appendix
Slide 35: Technology Comparison
Appendix Technology Comparison For personal use only • Compared to incumbent technology, XV Technology benefits from: ✓ Cost efficiency, being significantly cheaper than both a Pulmonary Function Test (PFT) and a thoracic CT scan ✓ Higher level of detail and accuracy ✓ 4D output, showing regional lu
Slide 36: USA Reimbursement Strategy
Appendix USA Reimbursement Strategy For personal use only Potential for a step change in adoption and revenue post reimbursement in 2023 Objective Drive rapid adoption and positive reimbursement for XV Technology with all Government and Commercial Payers Clinical study Payer Coding, Develop Develop
Slide 37: Contacts
Contacts For personal use only Corporate Investor Relations Media Charlene Stahr Simon Hinsley Matthew Wright Company Secretary +61 401 809 653 +61 451 896 420 companysecretary@4dmedical.com shinsley@4dmedical.com matt@nwrcommunications.com.au For more information please visit www.4DMedical.com